Neuro-oncology Unit, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
Department of Radiology, Rabin Medical Center, Petah Tikva, Israel.
J Clin Neurosci. 2021 Mar;85:20-26. doi: 10.1016/j.jocn.2020.11.050. Epub 2021 Jan 3.
Glioblastoma (GBM) typically presents as a single lesion. Multicentric GBM are defined as well separated lesions on MRI (enhancing and non-enhancing). Multicentric GBM with non-enhancing lesions (MNE-GBM) are rarely described in literature. We aimed at describing the radiologic characteristics, treatment, and clinical course of those patients. The institutional neuropathological database was searched for GBM patients diagnosed between 1/1/2015 and 31/05/2018. All pre-operative MRI brain scans were reviewed to identify patients with MNE-GBM. Electronic medical records and follow-up MRI scans were reviewed to assess progression-free survival (PFS) and overall survival (OS). Out of 149 adult patients with newly diagnosed GBM, 12 met the inclusion criteria of MNE-GBM, all of them presented at least one enhancing lesion. Median follow-up for the MNE-GBM patients was 16.1 months. At last follow-up, all patients had recurrence (median PFS 7.6 months) and eleven patients had deceased. Median OS was 16.2 months (95% CI, 4.1-27.5). Eleven patients received radiotherapy concomitant with temozolomide as initial treatment. Radiation field included all the disease foci (enhancing and non-enhancing lesions) in 8 patients, five of them progressed within the non-enhancing lesion. Three patients did not receive radiation for the entire non-enhancing lesions, and two of them progressed within the non-irradiated areas. In conclusion, MNE-GBM is not rare, and has high risk of aggressive progression within the separate non-enhancing lesion.
胶质母细胞瘤(GBM)通常表现为单个病变。多灶性 GBM 定义为 MRI 上明显分隔的病变(增强和非增强)。文献中很少描述多灶性 GBM 伴非增强病变(MNE-GBM)。我们旨在描述这些患者的放射学特征、治疗和临床过程。在 2015 年 1 月 1 日至 2018 年 5 月 31 日期间,我们从机构神经病理学数据库中搜索诊断为 GBM 的患者。所有术前脑部 MRI 扫描均用于识别 MNE-GBM 患者。回顾电子病历和随访 MRI 扫描以评估无进展生存期(PFS)和总生存期(OS)。在 149 名新诊断为 GBM 的成年患者中,有 12 名符合 MNE-GBM 的纳入标准,所有患者均至少存在一个增强病变。MNE-GBM 患者的中位随访时间为 16.1 个月。最后一次随访时,所有患者均复发(中位 PFS 7.6 个月),11 名患者死亡。中位 OS 为 16.2 个月(95%CI,4.1-27.5)。11 名患者接受替莫唑胺同步放化疗作为初始治疗。8 名患者的放射野包括所有病变灶(增强和非增强病变),其中 5 名在非增强病变内进展。3 名患者未对整个非增强病变进行放疗,其中 2 名在未放疗区域进展。总之,MNE-GBM 并不罕见,在单独的非增强病变中具有侵袭性进展的高风险。